PIK3CB: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 5
- Sponsors: 5
Who is on it, and how far along
Every drug ChEMBL records acting on PIK3CB, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AstraZeneca Pharmaceuticals120%
- Bayer120%
- Curis, Inc.120%
- GSK120%
- Sanofi120%
| GSK-2636771 | Phase 2 | GSK | Small molecule | Inhibitor | 3 |
| Fimepinostat | Phase 2 | Curis, Inc. | Small molecule | Inhibitor | 1 |
| AZD-8186 | Phase 1 | AstraZeneca Pharmaceuticals | Small molecule | Inhibitor | 0 |
| BAY-1082439 | Phase 1 | Bayer | Small molecule | Inhibitor | 0 |
| SAR-260301 | Phase 1 | Sanofi | Small molecule | Inhibitor | 0 |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease | Fimepinostat | Phase 2 | Recruiting | University of California, Los Angeles | Aug 2, 2023 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | GSK-2636771 | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jun 19, 2020 |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | GSK-2636771 | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jun 19, 2020 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | GSK-2636771 | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jun 8, 2015 |
- Cancer0.58
- Neurodegenerative disease0.53
- Alzheimer disease0.48
- Parkinson disease0.47
- Lysosomal storage disease0.46
- Non-small cell lung carcinoma0.46
- Breast cancer0.43
- Prostate adenocarcinoma0.41
- Head and neck squamous cell carcinoma0.40
- Kidney neoplasm0.38
- Esophageal adenocarcinoma0.37
- Lymphoid neoplasm0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3145, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P42338, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets